Leerink Partners analyst Mani Foroohar has maintained their bearish stance on MRNA stock, giving a Sell rating on January 27.
Mani Foroohar has given his Sell rating due to a combination of factors affecting Moderna’s stock. One significant concern is the recent Senate Finance Committee’s vote in favor of RFK Jr.’s nomination, which has led to apprehensions regarding its potential impact on vaccination rates and future regulatory decisions. This environment is seen as unfavorable for primary care vaccine producers like Moderna, as regulatory changes could negatively affect their market position and investor sentiment.
Additionally, Moderna’s stock has experienced volatility, with gains from earlier positive developments being reversed. The anticipation of a challenging CMV readout further adds to the pressure on the stock. These factors contribute to a cautious outlook, prompting Foroohar to recommend a Sell rating for Moderna’s shares.
According to TipRanks, Foroohar is an analyst with an average return of -10.8% and a 38.69% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Intellia Therapeutics.
In another report released on January 27, J.P. Morgan also maintained a Sell rating on the stock with a $40.00 price target.